Jörg Wischhusen

TL;DR: It is demonstrated that the TGF-β suppresses the antitumor function of ROR1-CAR T-cells against TNBC in preclinical models and supports the continued preclinical development and the clinical evaluation of combination treatments that shield CAR T- cells from T GF-β.

TL;DR: It is suggested that various cell types within a tumour cooperate in order to inhibit anti-tumour immunity-and that immunetolerogenic HLA-G may play a major role in this context.

TL;DR: In melanomas expressing high levels of wild type p53 this tumor suppressor is frequently inactivated at transcriptional level, which can be blocked by shRNA knock down of p53.

TL;DR: How clinically relevant doses promote NK cell effector functions are analyzed to argue for a careful timing and dosing of dasatinib application during leukemia/lymphoma treatment to enhance NK cell immunotherapeutic efforts.

TL;DR: Functional data reveal that the miR‐23a cluster not only is induced by TGF‐β, but also exerts a suppressive effect on CD8+ T‐cell effector functions, even in the absence of T GF‐β signaling.